Subunit Vaccines Suited For The Fight Against COVID-19

By Cynthia A. Challener

Protein subunit vaccines have a long history, but the COVID-19 pandemic has brought renewed attention to their potential and limitations. Because these vaccines contain only selected parts of a pathogen rather than the whole organism or genetic instructions, they are generally associated with good tolerability, although generating a strong immune response remains an important consideration.

In this article, contributing editor Cynthia A. Challener brings together perspectives from Lonza specialists in microbial development, regulatory affairs, commercial development, and supply chain, alongside commentary from a Novavax spokesperson. The discussion examines where protein subunit vaccines may offer advantages over genetic vaccine approaches and considers the regulatory and cost-related hurdles that can affect their development. It further explores advances over the preceding decade that are influencing vaccine formulation and manufacturing strategies. Against the backdrop of the COVID-19 response, the contributors consider the role of protein subunit candidates in the broader vaccine landscape.

Access these industry perspectives below to understand the opportunities, practical challenges, and emerging developments shaping the future of protein subunit vaccines.